THE INDUSTRY’S LARGEST MARKETPLACE FOR PHARMACEUTICALS
steroidify.xyz has been in operation for almost 30 years, acquiring 50’s of thousands of satisfied customers.
steroidify.xyz works very hard to establish trust with our customer. Our high-quality products and professional staff is testament to the legitimacy of our business practice.
Each brand is hand-selected and goes through a very thorough review process.
Quality is held in a very high regard at steroidify.xyz. To further legitimize these products, we do have a comprehensive
Featured
MK677 10 (Ibutamoren)
ACTIVE HALF-LIFE 24 hours CLASSIFICATION Growth Hormone Secretagogue DOSAGE 10-50 mg/day MANUFACTURER De..
Trenbomed E 200
ACTIVE HALF-LIFE 5-7 Days CLASSIFICATION Anabolic Steroid DOSAGE Men 200-600 mg/week ACNE Rarely WATER RETENTION ..
Dropoetin 2000IU
PRODUCT CLASSIFICATION Glycoprotein Cytokine ACNE No WATER RETENTION No HBR No HEPATOTOXICITY ..
Provimed 25
ACTIVE HALF-LIFE 12 hours CLASSIFICATION Anabolic Steroid DOSAGE Men 25-100 mg/day ACNE Yes ..
PHARMA MIX 2
ACTIVE HALF-LIFE 2-3 days CLASSIFICATION Anabolic Steroid DOSAGE Men: 500-750 mg/week ACNE Yes WATER RETENTION..
Oxymetos
ACTIVE HALF-LIFE 8 Hours CLASSIFICATION Anabolic Steroid DOSAGE Recommended for Men: 50-100 mg/day ACNE Yes WA..
Ultima-Enan 250
ACTIVE HALF-LIFE 5-7 Days CLASSIFICATION Anabolic Steroid DOSAGE Men: 300-1500 mg/week ACNE Yes ..
Cipronatin 500
CLASSIFICATION Antibiotic, Fluoroquinolone MANUFACTURER Atabay WAREHOUSE International Warehouse 2 ACTIVE INGREDIENT Ciprofloxacin What is Ciprof..
Ultima-Deca 250
ACTIVE HALF-LIFE 6-7 days CLASSIFICATION Anabolic Steroid DOSAGE Men: 300-600 mg/week ACNE Rarely WATER RETENT..
1-Test Cyp 100
ACTIVE HALF-LIFE 10-12 Days CLASSIFICATION Anabolic Steroid DOSAGE Recommended for Men: 100-200 mg/week ACNE ..
Ultima-Ipamorelin 10mg
MANUFACTURER Ultima Pharmaceuticals - USA WAREHOUSE USA Warehouse 5 ACTIVE INGREDIENT Ipamorelin For your privacy..
DES (1-3) 1mg
ACNE No WATER RETENTION No HBR No HEPATOTOXICITY No AROMATIZATION No MANUFACTURER ..











